Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 317
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
AMG 317 is a fully human monoclonal antibody that targets the interleukin-4 receptor subunit alpha (IL-4Rα), thereby blocking both IL-4 and IL-13 signaling pathways. These cytokines are key mediators in allergic airway inflammation and play a significant role in the pathogenesis of asthma. Developed by Amgen as an antiasthmatic agent, AMG 317 was evaluated for efficacy and safety in patients with moderate to severe asthma. While it demonstrated some clinical activity—particularly among patients with more severe or uncontrolled symptoms—it did not show statistically significant efficacy across the overall study population. The drug was well tolerated but its development for asthma has been discontinued[1][2][3][5].
- Other names
- AMG 317AMG317AMG-317ANTI-IL-4RANTI-IL4RANTI-IL 4RAnti-interleukin-4 receptor antibodyAnti-interleukin4 receptor antibodyAnti-interleukin 4 receptor antibody
02
Targets
IL13RA2 (Interleukin-13 receptor subunit alpha 2)IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on AMG 317.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 317.